antiviral and associated therapy - all results

Treatment	Number of studies	Demonstrated or suggested results	Inconclusive results	Uncertain results	Safety results
chloroquine and derivatives	4 studies[1]		inconclusive results for : death D28 ; deaths ; deaths (time to event analysis only) ; clinical deterioration ; clinical improvement (time to event analysis only) ; hospital discharge ; ICU admission ; off oxygenation	suggested 86	
ivermectin	3 studies[2]		inconclusive results for : deaths ; deaths (time to event analysis only) ; clinical improvement ; clinical improvement (7-day) ; viral clearance ; ICU admission	suggested 86	
lopinavir/ritonavir	2 studies[3]		inconclusive results for : deaths ; deaths (time to event analysis only) ; clinical improvement ; clinical improvement (14-day) ; clinical improvement (28-day) ; clinical improvement (7-day) ; clinical improvement (time to event analysis only) ; death or ventilation ; hospital discharge ; serious adverse events		
azithromycin	1 study[4]		inconclusive results for : death D28 ; deaths ; deaths (time to event analysis only) ; clinical improvement ; clinical improvement (14-day) ; clinical improvement (28-day) ; clinical improvement (7-day) ; related SAE (TRSAE) ; serious adverse events ; long QT ; renal impairment		
favipiravir	1 study[5]		inconclusive results for : deaths ; hospital discharge		

Continued on next page

Treatment	Number of studies	Demonstrated or suggested results	Inconclusive results	Uncertain results	Safety results
Lopinavir/ritonavir plus hydroxychloroquine	1 study[6]		inconclusive results for : clinical improvement ; clinical improvement (14-day) ; hospital discharge ; serious adverse events	suggested 42	
remdesivir	1 study[7]		inconclusive results for : deaths ; clinical deterioration ; clinical improvement ; clinical improvement (14-day) ; clinical improvement (28-day) ; clinical improvement (7-day) ; clinical improvement (time to event analysis only) ; AE leading to drug discontinuation ; serious adverse events ; deep vein thrombosis ; elevated liver enzymes ; hyperbilirubinemia ; pulmonary embolism ; renal impairment		
sofosbuvir and daclatasvir	1 study[8]		inconclusive results for : adverse events	suggested 88	

Uncertain results are statistically significant results but obtain in trial with high risk of bias.
Demonstrated results are significant results obtained on the primary endpoint of a trial at low risk of bias or with some concerns.

Notes

[1]HYDRA (Hernandez-Cardenas), 2021 (NCT04315896) ; REMAP-CAP-HCQ, 2020 (NCT02735707) ; Mahevas, 2020 () ; Yu, 2020 ()
[2]Galan, 2021 (RBR-8h7q82) ; Okumuş, 2020 (NCT04646109) ; Camprubi, 2020 ()
[3]Cao, 2020 (ChiCTR2000029308) ; REMAP-CAP (lopinavir/ritonavir only), 2020 (NCT02735707)
[4]COALITION II Covid-19 Brazil (Furtado), 2020 (NCT04321278)
[5]Kocayigit H, 2020 ()
[6]REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 (NCT02735707)
[7]CAP-China (Wang et al.), 2020 (NCT04257656)
[8]Eslami, 2020 (IRCT20200324046850N2)